Powering The iPhone: Apple's Supply Chain Partners
Apple's recent record-breaking revenue highlights the success of its strategic supply chain diversification. This creates a compelling investment opportunity in the key component and manufacturing partners that are essential to Apple's production ecosystem.
Your Basket's Financial Footprint
Parsed market capitalisation breakdown for the basket named 'Powering The iPhone: Apple's Supply Chain Partners'. Includes total market cap and constituent market caps.
- Large-cap dominance generally implies lower volatility and closer market tracking, so performance tends to be steadier, less speculative.
- Best considered a core holding for diversified portfolios, offering broad exposure rather than a speculative growth position.
- Expect steady long-term value appreciation rather than explosive short-term gains; outcomes are not guaranteed.
TSM: $1.23T
ASML: $400.56B
LRCX: $182.63B
- Other
About This Group of Stocks
Our Expert Thinking
Apple's record-breaking $94.04 billion quarterly revenue, driven by strong iPhone 16 sales, creates a powerful ripple effect throughout its supply chain. As Apple ramps up production to meet sustained demand, the companies that manufacture semiconductors, camera modules, and provide assembly services are positioned to benefit directly from this success.
What You Need to Know
This group focuses on the essential but often overlooked partners in Apple's manufacturing ecosystem. These companies range from advanced semiconductor manufacturers to component suppliers, all playing critical roles in bringing iPhones to market. Their fortunes are closely tied to Apple's continued market leadership and production needs.
Why These Stocks
Each company in this group has been handpicked by professional analysts based on their integral role in Apple's supply chain diversification strategy. These aren't random tech stocks - they're the specific manufacturers and suppliers that Apple relies on to maintain its production capabilities and meet global demand.
Why You'll Want to Watch These Stocks
Riding Apple's Record Success
With Apple's $94.04 billion quarterly revenue beating expectations, these supply chain partners are positioned to benefit directly from increased production demands and sustained iPhone momentum.
Essential Links in the Chain
These aren't just any tech companies - they're the critical manufacturers and suppliers that Apple depends on for semiconductors, components, and assembly services to keep iPhones flowing to market.
Strategic Diversification Play
Apple's supply chain diversification strategy creates opportunities for multiple partners across different regions, reducing single-point risks while opening doors for growth across the ecosystem.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Aerospace Stocks: Could Airbus Issues Boost Boeing?
Airbus has cut its delivery targets after discovering a significant fuselage flaw in its A320 aircraft, causing production delays and requiring widespread inspections. This situation could create a significant opening for its main competitor, Boeing, and other aerospace manufacturers to capture market share from airlines seeking to avoid delivery uncertainties.
Cargo Capacity Crisis: Which Stocks May Benefit Most?
The crash of a UPS cargo plane has led to the grounding of an entire class of aging aircraft across the logistics industry. This creates a potential investment opportunity in competing cargo carriers and aircraft manufacturers poised to fill the resulting gap in shipping capacity.
UK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.